Elita raises A$1.9 million to push preventive dog care into the home

The Melbourne startup is connecting longitudinal health records, at-home biological testing and around-the-clock veterinary access in one preventive-care platform.

By Good Company Editorial Desk

THE NEWS

Australian pet-health startup Elita has raised A$1.9 million to expand its preventive-care platform for dogs and develop an at-home biological testing product called Blueprint360. Boost VC backed the round alongside Gandel Invest, Artesian's Female Leaders Fund, Touch Ventures and M8 Ventures. Elita was founded in Melbourne in December 2024 by Paloma Newton and Jackson Gritching. Its core product, Elita Blueprint, is designed to combine veterinary records, biological test results and information supplied by owners into a health profile that changes with the dog over time.

THE NUMBERS

The new financing follows a A$1.1 million pre-seed round reported in July 2025, bringing Elita's disclosed funding across the two rounds to A$3 million. The company says Blueprint360 is being developed in-house and is scheduled to launch later in 2026. Elita has also partnered with Australian telehealth provider VetChat to offer 24/7 access to local veterinarians. Under that arrangement, participating veterinarians can review a dog's Blueprint history before a consultation.

WHY IT MATTERS

Elita is betting that pet health can move from episodic appointments toward a continuous record. The commercial opportunity is not just a test kit or a telehealth visit. It is the layer that connects data generated at home with veterinary context. If owners keep their records current and veterinarians find the history useful, the platform could make virtual visits more informed and give Elita a recurring relationship with households between clinic appointments.

WHAT TO WATCH

The next proof points are practical: what Blueprint360 measures, how results are validated, how much it costs and whether veterinarians act differently with the added information. Adoption will also depend on how smoothly records move into the platform and how Elita handles sensitive health data. Until the product launches and those details are public, the financing is best read as capital to test a preventive-care model, not proof that the model has already scaled.

Sources

International Pet Food; CFOtech. Reporting is based on disclosed announcements and cited coverage; undisclosed terms and open questions are identified in the story.